Product Information
FLUPHENAZINE 2.5 MG TABLET is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.2237 per EA under NDC 70954027410. Its NADAC has been published 268 times since Aug 18, 2021.
FDA first approved this application on Mar 1, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Fluphenazine Hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2.5 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
70954027410
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FLUPHENAZINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA214674FDA Approved
3/1/2021
TE Code
AB
On Market Since
3/1/2021
Pharmacological Classes
Price Statistics
The NADAC for FLUPHENAZINE 2.5 MG TABLET has been published 268 times since Aug 18, 2021, and over the history we have for it it has declined 91.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2237 per EA |
|---|---|
| All-time high | $2.7666 (Sep 15, 2021) |
| All-time low | $0.2046 (Jul 22, 2026) |
| 52-week high | $0.4964 |
| 52-week low | $0.2046 |
| Median price | $0.6092 |
| Average price | $0.8944 |
| Largest weekly change | +57.5% (Jun 21, 2023) |
| Weeks tracked | 268 |
| Tracking since | Aug 18, 2021 |
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fluphenazine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phenothiazine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FLUPHENAZINE 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FLUPHENAZINE 2.5 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $0.2237 per EA (NDC 70954027410), effective Sep 30, 2026.
How has the price of FLUPHENAZINE 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for FLUPHENAZINE 2.5 MG TABLET has declined 91.9%. It has been tracked across 268 weekly CMS publications since Aug 18, 2021.
What are the highest and lowest recorded NADAC prices for FLUPHENAZINE 2.5 MG TABLET?
Since Aug 18, 2021, the NADAC for FLUPHENAZINE 2.5 MG TABLET has ranged from a low of $0.2046 (Jul 22, 2026) to a high of $2.7666 (Sep 15, 2021), with a median of $0.6092 per EA.
Are there cheaper alternatives to FLUPHENAZINE 2.5 MG TABLET?
Yes. 11 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FLUPHENAZINE 2.5 MG TABLET, is $0.2208 per EA — about 1% below FLUPHENAZINE 2.5 MG TABLET.
Who manufactures FLUPHENAZINE 2.5 MG TABLET?
FLUPHENAZINE 2.5 MG TABLET (NDC 70954027410) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.